What is the significance of a 1.5 cm mass in the perinephric space adjacent to the surgical bed, 3 years after partial nephrectomy for a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The 1.5 cm mass in the perinephric space adjacent to the surgical bed, 3 years after partial nephrectomy for a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a, is likely a benign post-surgical change, and given the low-risk nature of the initial tumor, there is no cause for concern regarding recurrence. The patient's history of partial nephrectomy for a low-risk tumor, such as a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a, suggests a favorable prognosis, with most recurrences occurring within 3 years after treatment 1. Given the timing and location of the mass, it is essential to consider the possibility of post-surgical changes, which can evolve over time and may be difficult to distinguish from recurrence without thorough evaluation 1. The American College of Radiology (ACR) Appropriateness Criteria for post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma recommend imaging surveillance of the chest and abdomen after primary treatment for RCC, with more frequent follow-up for intermediate- and high-risk tumors 1. For low-risk/T1 tumors, such as the patient's initial diagnosis, the recommended follow-up protocol includes chest imaging every 12 to 24 months for 3 to 5 years and abdominal imaging, with some recommending a baseline study between 3 and 12 months, especially after partial nephrectomy, then yearly for 3 to 5 years 1. In this case, the patient's 3-year follow-up scan showing a 1.5 cm mass in the perinephric space adjacent to the surgical bed does not necessarily indicate recurrence, especially considering the low-risk nature of the initial tumor and the possibility of benign post-surgical changes 1. Therefore, continuing with the regular follow-up schedule as recommended by the urologist is essential, but these specific findings do not represent a cause for concern regarding recurrence of the chromophobe renal cell carcinoma.

From the Research

Clinical Significance of a 1.5 cm Mass in the Perinephric Space

The presence of a 1.5 cm mass in the perinephric space adjacent to the surgical bed, 3 years after partial nephrectomy for a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a, may indicate a potential recurrence or a new primary tumor.

  • The mass could be a recurrence of the chromophobe RCC, given that chromophobe RCCs can have a variable clinical course and may recur even after surgical resection 2.
  • Alternatively, the mass could be a new primary tumor, such as a clear cell RCC or another subtype of RCC, as renal cell carcinoma is a heterogeneous group of neoplasms derived from the renal tubular epithelial cells 3.
  • The diagnosis and prognosis of chromophobe RCC can be challenging due to its morphological variance, and a generally accepted prognostically convincing graduation scheme has not yet been developed 4.
  • The treatment and prognosis of chromophobe RCC depend on various factors, including the tumor size, stage, and grade, as well as the presence of any aggressive morphologic features such as necrosis and sarcomatoid features 5, 6.

Diagnostic Considerations

To determine the nature of the 1.5 cm mass, further diagnostic evaluation is necessary, including:

  • Imaging studies, such as CT or MRI, to characterize the mass and assess for any evidence of local recurrence or metastatic disease.
  • Biopsy or surgical excision of the mass to obtain a histopathologic diagnosis and determine the tumor subtype and grade.
  • Molecular analysis to identify any genetic alterations or biomarkers that may be associated with the tumor, such as TP53 and PTEN mutations in chromophobe RCC 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Chromophobe Renal Cell Carcinoma with Radiologic-Pathologic Correlation.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2021

Research

Chromophobe renal cell carcinoma: a review of an uncommon entity.

International journal of urology : official journal of the Japanese Urological Association, 2012

Related Questions

What is the significance of a 1.5 cm mass in the perinephric space adjacent to the surgical bed, 3 years after partial nephrectomy for a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a?
What is the significance of a 3 mm solid nodule anterior to the psoas muscle in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC)?
What is the significance of a 3 mm nodule near the left kidney in a patient with a history of partial nephrectomy for Chromophobe renal cell carcinoma (RCC)?
Is a 3 mm nodule in the fat anterior to the psoas muscle, which has become more prominent over 3 years, more likely a malignant or benign process following a partial nephrectomy for a 1.3 cm exophytic Chromophobe renal cell carcinoma (RCC)?
What is the significance of a 3 mm nodule found in the fat anterior to the psoas muscle, below the lower pole of the left kidney, on imaging 3 years after a partial nephrectomy for a 1.3 cm exophytic Chromophobe renal cell carcinoma (RCC)?
What is best said for acute lower back pain?
Is a 1-week embryo with Mosaicism (MOSAIC), specifically 50% XY and 22 chromosome abnormalities, a viable result for transfer?
What is the most effective Non-Steroidal Anti-Inflammatory Drug (NSAID) for acute lower back pain?
What is the comparative efficacy of cyclobenzaprine (Flexeril) versus methocarbamol (Robaxin) for the treatment of cervical pain (neck pain)?
What is the treatment for onychomycosis?
What is the likely diagnosis of a 3mm nodule, previously thought to be new, but determined to be a pre-existing lesion that has become more visible on computed tomography (CT) imaging due to improved resolution, in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.